Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: A bronchoalveolar lavage study

Fibrogenesis and Tissue Repair

Volumn 3, Issue 1, 2010, Pages

  Margaritopoulos, Giorgos A ^a,b   Antoniou, Katerina M ^a,b   Karagiannis, Kostas ^b   Samara, Katerina D ^a,b   Lasithiotaki, Ismini ^b   Vassalou, Evi ^b   Lymbouridou, Rena ^b   Koutala, Helen ^b   Siafakas, Nikos M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COLLAGEN DISEASE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; FORCED VITAL CAPACITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SARCOIDOSIS; SEX DIFFERENCE; UPREGULATION;

EID: 79960429928     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-3-20     Document Type: Article

References (44)

1. Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003, 29:S93-S97.
2. Kottmann RM, Hogan CM, Phipps RP, Sime PJ. Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology 2009, 14:917-933. 10.1111/j.1440-1843.2009.01624.x, 19740254.
3. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007, 357:2153-2165. 10.1056/NEJMra071714, 18032765.
4. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004, 76:514-519. 10.1189/jlb.0304127, 15178705.
5. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5. 10.1189/jlb.0306164, 17032697.
6. Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol 2006, 91:159-173. full_text, 16938540.
7. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511. 10.1038/nri1391, 15229469.
8. Droemann D, Goldmann T, Branscheid D, Clark R, Dalhoff K, Zabel P, Vollmer E. Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol 2003, 119:103-108.
9. Morris GE, Whyte MK, Martin GF, Jose PJ, Dower SK, Sabroe I. Agonists of toll-like receptors 2 and 4 activate airway smooth muscle via mononuclear leukocytes. Am J Respir Crit Care Med 2005, 171:814-822. 10.1164/rccm.200403-406OC, 15657467.
10. Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O'Neill SJ, McElvaney NG. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol 2005, 174:1638-1646.
11. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007, 117:530-538. 10.1172/JCI30595, 1804377, 17332880.
12. Meneghin A, Choi ES, Evanoff HL, Kunkel SL, Martinez FJ, Flaherty KR, Toews GB, Hogaboam CM. TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol 2008, 130:979-992. 10.1007/s00418-008-0466-z, 18633634.
13. Yang HZ, Cui B, Liu HZ, Chen ZR, Yan HM, Hua F, Hu ZW. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol 2009, 182:692-702.
14. Saboor SA, Johnson NM, McFadden J. Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet. 1992, 339:1012-1015. 10.1016/0140-6736(92)90535-B, 1349051.
15. Abe C, Iwai K, Mikami R, Hosoda Y. Frequent isolation of Propionibacterium acnes from sarcoidosis lymph nodes. Zentralbl Bakteriol Mikrobiol Hyg A 1984, 256:541-547.
16. Wikén M, Grunewald J, Eklund A, Wahlström J. Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis. J Clin Immunol 2009, 29:78-89. 10.1007/s10875-008-9225-0, 18773284.
17. Schürmann M, Kwiatkowski R, Albrecht M, Fischer A, Hampe J, Müller-Quernheim J, Schwinger E, Schreiber S. Study of Toll-like receptor gene loci in sarcoidosis. Clin Exp Immunol 2008, 152:423-431. 10.1111/j.1365-2249.2008.03621.x, 2453194, 18422738.
18. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P, Boumpas DT. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006, 54:3601-3611. 10.1002/art.22197, 17075805.
19. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005, 52:2656-2665. 10.1002/art.21273, 16142732.
20. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, van den Berg WB, Radstake TR. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005, 52:2313-2322. 10.1002/art.21278, 16052591.
21. Kyburz D, Rethage J, Seibl R, Lauener R, Gay RE, Carson DA, Gay S. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003, 48:642-650. 10.1002/art.10848, 12632416.
22. Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009, 21:617-622. 10.1097/BOR.0b013e32832fd69e, 19633559.
23. Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL, Gregersen PK, Behrens TW. Gene expression profiling in human autoimmunity. Immunol Rev 2006, 210:120-137. 10.1111/j.0105-2896.2006.00367.x, 16623768.
24. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002, 165:277-304. American Thoracic Society/European Respiratory Society International.
25. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related. Am J Respir Crit Care Med 2007, 175:705-711. 10.1164/rccm.200607-912OC, 17218621.
26. American Rheumatism Association Diagnostic and Therapeutic Criteria Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1988, 23:581-590. American Rheumatism Association Diagnostic and Therapeutic Criteria Subcommittee for Scleroderma.
27. Arnett FC, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
28. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999, 16:149-173.
29. Antoniou KM, Tzouvelekis A, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Rachiotis G, Tzanakis N, Bouros D, Milic-Emili J, Siafakas NM. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 2006, 130:982-988. 10.1378/chest.130.4.982, 17035428.
30. Haslam PL, Baughman RP. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J 1999, 14:245-248. 10.1034/j.1399-3003.1999.14b01.x, 10515395.
31. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006, 29:305-314.
32. Antoniou KM, Soufla G, Proklou A, Margaritopoulos G, Choulaki C, Lymbouridou R, Samara KD, Spandidos DA, Siafakas NM. Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study. Clin Dev Immunol 2009, 2009:537929, 2821758, 20169144.
33. Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 2003, 124:1866-1878. 10.1016/S0016-5085(03)00403-7, 12806620.
34. Keane MP, Arenberg DA, Lynch JP 3, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997, 159:1437-1443.
35. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009, 33:882-896. 10.1183/09031936.00152607, 19336591.
36. Margaritopoulos GA, Antoniou KM, Soufla G, Karagiannis K, Proklou A, Lasithiotaki I, Tzanakis N, Spandidos DA, Siafakas NM. Upregulation of stromal cell derived factor-1alpha in collagen vascular diseases-associated interstitial pneumonias (CVDs-IPs). Pulm Pharmacol Ther 2010, 23:115-120. 10.1016/j.pupt.2009.10.008, 19878731.
37. Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 2000, 55:958-961. 10.1136/thorax.55.11.958, 1745627, 11050267.
38. Yonemaru M, Kasuga I, Kusumoto H, Kunisawa A, Kiyokawa H, Kuwabara S, Ichinose Y, Toyama K. Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur Respir J 1997, 10:2040-2045. 10.1183/09031936.97.10092040, 9311499.
39. Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, Brigham KL, Oates JA, Loyd JE, Stecenko AA. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003, 41:2633-2640. 10.1128/JCM.41.6.2633-2640.2003, 156536, 12791891.
40. Searle J, Kerr JF, Bishop CJ. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol Annu 1982, 17(Pt 2):229-259.
41. Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, Nicholson AG, du Bois RM, Wells AU. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 2008, 177:190-194. 10.1164/rccm.200612-1759OC, 17962635.
42. Symvoulakis EK, Zaravinos A, Panutsopulos D, Zoras O, Papalambros E, Sigala F, Spandidos DA. Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. Int J Biol Markers 2007, 22:12-18.
43. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005, 6:68. 10.1186/1465-9921-6-68, 1187924, 16004610.
44. Noakes PS, Hale J, Thomas R, Lane C, Devadason SG, Prescott SL. Maternal smoking is associated with impaired neonatal toll-like-receptor-mediated immune responses. Eur Respir J 2006, 28:721-729. 10.1183/09031936.06.00050206, 16870663.